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Our study underscores the need to critically evaluate whetherEffects of different PPAR-agonists on MCP-1 expression and
PPAR ligands will have beneficial or possibly deleteriousmonocyte recruitment in experimental glomerulonephritis.
effects in GN.Background. Activators of peroxisome proliferator activated
receptor  (PPAR) have been shown to modulate chemokine
expression in isolated monocytes/macrophages (M/M) and to
exert anti-inflammatory effects in some models of experimental The peroxisome proliferator-activated receptor inflammatory diseases. We evaluated the effects of different
(PPAR) is a member of the family of nuclear receptorsforms of PPAR activators in a model of experimental glomer-
of ligand-activated transcription factors that include ste-ulonephritis (GN) in rats.
Methods. GN was induced in rats by application of an anti- roid, retinoid, and thyroid hormone receptors [1]. The
thymocyte antibody (ATS). Nephritic rats were treated with PPARs form heterodimers with the 9-cis retinoic acid re-
two synthetic PPAR ligands of the thiazolidinedione (TZD) ceptor, RXRa, and bind to characteristic DNA sequences
group, troglitazone (200 mg/kg/day) and ciglitazone (100 mg/kg/
termed peroxisome proliferator response elements (PPRE)day), and with a natural ligand 15d-PGJ2 (1.5 mg/day). Twenty-
located in the promoter region of target genes. Threefour hours after induction of the GN, the glomerular mRNA
isoforms of PPAR (PPAR, PPAR and PPAR) haveexpression of the chemokine monocyte chemoattractant pro-
tein-1 (MCP-1) and the cognate chemokine receptor CCR-2 been described [2]. PPAR is expressed at high levels
were examined by Northern blotting and RT-PCR. The glo- in adipose tissues and plays a crucial role in lipid metabo-
merular M/M infiltration was determined by immunohistology. lism and glucose homeostasis [3]. A structurally diverseThe activation of the transcription factors PPAR, nuclear
group of compounds, naturally occurring fatty acid deriv-factor-B (NF-B) and activator protein-1 (AP-1) in glomeruli
atives, eicosanoids (such as 15d-PGJ2) and synthetic mol-was analyzed by electrophoretic mobility shift assay.
Results. Induction of GN up-regulated glomerular nuclear ecules [such as thiazolidinediones (TZD), for example,
protein binding of NF-B and AP-1. Treatment of nephritic rats troglitazone and ciglitazone] can bind and activate these
with troglitazone and ciglitazone augmented nuclear PPAR receptors [4, 5]. PPAR ligands of the TZD group lowerand AP-1 DNA binding but did not affect NF-B binding.
blood glucose levels and are in use as potent anti-diabeticTZD enhanced glomerular MCP-1 expression and increased
drugs in humans [6]. They protect against the develop-glomerular M/M recruitment. In contrast, 15d-PGJ2 attenuated
NF-B activation and did not affect AP-1 activity or MCP-1 ment and progression of diabetic nephropathy [7, 8] and
expression. nondiabetic glomerulosclerosis in rats [9]. Recent reports
Conclusion. Our data show that PPAR activators of the show that PPAR is expressed in monocytes/macro-
TZD group, but not 15d-PGJ2, enhance MCP-1 expression and phages (M/M) and that activators of PPAR can modu-M/M infiltration in the induction phase of experimental GN.
late their activation and down-regulate their expressionThe results demonstrate that TZD and 15d-PGJ2 may exert
different effects in the immune response in experimental GN. of inflammatory cytokines and chemokines [10–12]. Con-
troversy exists, however, since other studies demon-
strated pro-inflammatory rather than anti-inflammatory
1 Drs. Panzer and Schneider contributed equally to this work. effect of PPAR ligands on the expression of cytokines
and chemokines in M/M [13, 14]. Furthermore, severalKey words: activator protein-1, nuclear factor-B, troglitazone, ciglita-
studies demonstrated differences between the effects ofzone, peroxisome proliferator activated receptor , monocyte chemoat-
tractant protein-1, 15d-PGJ2. the synthetic PPAR agonists of the TZD group and
the natural PPAR ligand 15d-PGJ2 on nuclear factor-BReceived for publication July 30, 2001
(NF-B) and activator protein-1 (AP-1) dependent geneand in revised form March 14, 2002
Accepted for publication March 19, 2002 expression [15, 16]. Thus, the role of PPAR activators
in the setting of inflammation remains controversial. 2002 by the International Society of Nephrology
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Fig. 1. Effects of troglitazone on glomerular
monocyte chemoattractant protein-1 (MCP-1)
and its chemokine receptor (CCR-2) expres-
sion. Glomerular mRNA levels of MCP-1 in
control animals, nephritic animals, control an-
imals treated with troglitazone, and nephritic
animals treated with troglitazone assessed by
Northern blotting (A). RT-PCR analysis of
glomerular RNA of the chemokine receptors
CCR-2 (B). Quantification analysis of RNA
expression experiments are shown below.
Data are given as means  SEM (#P  0.05
vs. control; *P  0.05 vs. nephritis).
In several forms of glomerulonephritis, the activation METHODS
and infiltration of M/M in glomeruli and the tubulointer- Induction of glomerulonephritis and
stitium is a typical pathological feature closely correlated experimental design
to disease progression. The recruitment of M/M into in-
Immune-mediated mesangial cell injury was inducedjured tissues is largely dependent on a group of cytokines
in male Wistar rats (180 to 200 g/BW) by IV injectioncalled chemokines [17]. Among these chemokines, mono-
of an anti-rat-thymocyte antiserum (ATS). ATS was in-cyte chemoattractant protein-1 (MCP-1) [18] is an im-
duced in rabbits by repeated immunization with thymo-portant mediator for M/M infiltration in several forms
cytes from Lewis rats as described earlier [22].of experimental glomerulonephritis [19–21].
Eight different groups of animals (total N 140) wereTo investigate a possible role of different PPAR acti-
vators in the modulation of M/M attraction into glomer- studied at 24 hours after nephritis induction. For each
uli and on the course of GN, the effects of troglitazone, experimental setup groups of four animals were com-
ciglitazone and 15d-PGJ2 were studied in a rat model of pared, the experimental setup was repeated at least two
mesangial immune GN. times. Experiments with troglitazone were performed
Our results demonstrate that stimulation of PPAR four times. Control rats (N  32) received 0.5 mL/100 g
through troglitazone and ciglitazone increases MCP-1 BW of non-antibody IgG intravenously. Nephritic rats
expression and M/M recruitment in the early stage of a (N  32) received 0.5 mL/100 g BW of ATS intrave-
rat model of mesangial immune glomerulonephritis, and nously. Control and nephritic rats treated with troglita-
suggest that these effects are partly mediated through
zone (N  52) received 20, 50, 200 and 500 mg/kg BW ofan enhanced binding activity of the nuclear transcription
troglitazone per day in a 1% methylcellulose suspensionfactor AP-1. In contrast, application of 15d-PGJ2 reduces
orally. Control and nephritic rats treated with ciglitazoneNF-B activation and did not exert pro-inflammatory
(N  12) received 100 mg/kg BW ciglitazone orally pereffects. These results demonstrate the complex role of
day in a 1% methylcellulose suspension orally. ControlPPAR activation in the setting of inflammatory disease
and nephritic rats treated with 15d-PGJ2 (N  12) re-and underscore the need of a careful evaluation of possi-
ble deleterious effects of PPAR activators in GN. ceived 1.5 mg/kg BW 15d-PGJ2 daily in normal saline
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Fig. 2. Effect of ciglitazone and 15d-PGJ2 on glomerular MCP-1 and CCR-2 expression. Treatment of nephritic animals with ciglitazone enhanced
glomerular mRNA levels of MCP-1 assessed by Northern blotting (A) and CCR-2 analyzed by RT-PCR (B) when compared to untreated nephritic
animals. In contrast, treatment with 15d-PGJ2 did not increase glomerular MCP-1 and CCR-2 RNA expression. Quantification analysis of RNA
expression experiments are shown below
subcutaneously. In all groups medication was started 24 bers of ED-1 and PCNA positive cells are given per
hours before the induction of the disease and continued glomerular cross section as means  SEM.
until sacrifice.
Isolation of glomeruli, preparation of total RNA, and
Northern blot hybridization
Histology
Glomeruli were isolated by a fractional sieving tech-
Renal tissue was fixed in 4% buffered formaldehyde. nique using 90 m and 53 m mesh wire sieves, cellular
Paraffin embedded sections (2 m) were either stained RNA from glomeruli was isolated and 10 to 20 g of
with an antibody directed against the monocyte specific
total RNA was used for Northern blot analysis. A ratmarker ED-1 (Chemicon International, Temecula, CA,
MCP-1 cDNA fragment was used for hybridization.USA) to evaluate glomerular M/M infiltration or with
Membranes were rehybridized with a cDNA probe foran antibody against the proliferative cell nuclear antigen
human 18 S RNA to account for small loading and trans-(PCNA; Dakopatts M879, Hamburg, Germany). Tissue
fer variabilities. Densities on exposed films were quanti-sections were developed with the alkaline phosphatase
fied using a phosphoimager Bio-Rad-GS-363 Systemanti-alkaline phosphatase (APAAP) technique. ED-1
(multi-analyst software; Bio-Rad, Munich, Germany).and PCNA positive cells in 50 glomeruli per kidney were
Data analysis of Northern blot experiments was per-counted by light microscopy in a blinded fashion where
formed using three independent sets of experiments, andthe tissue source was unknown. Four different kidneys
of each group were evaluated at 24 hours. The cell num- the results are shown as mean  SEM.
Fig. 4. Immunohistologic staining of glomerular monocytes/macrophages (M/M) infiltration. Immunohistologic staining of glomerular M/M infiltra-
tion with an ED-1 antibody revealed a marked increase of glomerular ED-1 positive cells 24 hours after induction of the ATS-nephritis (B) in
comparison to non-nephritic animals (A) and the troglitazone treated animals (C ). Treatment of nephritic animals with troglitazone (D) further
enhanced glomerular M/M recruitment (	1000).
Fig. 8. Immunohistologic staining against PCNA. Compared with controls (A) and the troglitazone treated control group (C) nephritic animals
(B) and troglitazone treated nephritic rats (D) revealed a markedly increase in PCNA positive cells 5 days after nephritis induction (	1000).
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RT-PCR platform at 400 rpm for 15 minutes. Nuclear protein
extracts were obtained after centrifugation at 15,000 	For reverse transcription-polymerase chain reaction
g for five minutes. Protein concentration was determined(RT-PCR) 1 g of total RNA, 4 L 5	 First strand
using DC protein assay (Bio-Rad Laboratories), aliquotsbuffer, 1 L dNTPs (20 mmol/L), 2 L dithiothreitol
were stored at 
80C. EMSA was performed using a(DTT; 0.1 mol/L), 0.4 L poly(dT) primer (1 mg/mL;
PPAR (5-GGA CCA GGA CAA AGG TCA CGTPharmacia, Freiburg, Germany), 0.4 L RNasin (Pro-
TC 3) [25], NF-B (5-AGT TGA GGG GAC TTTmega, Madison, WI, USA), and 1 L Molony-murine
CCC AGG C 3) (Promega), and AP-1 (5 CGC TTGleukemia virus (M-MLV) reverse transcriptase (2 U/mL;
ATG AGT CAG CCG GAA 3) (Promega) consensusGibco BRL, Eggenstein, Germany) per sample were
oligonucleotide probe that was end-labeled with 32Pmixed. The RT reaction was carried out for two hours
ATP (3,000 Ci/mmol; Amersham Pharmacia Biotech,at 37C. Exact primer sequences for CCR-2 and MCP-1
Freiburg, Germany) according to the manufacturer’s in-are available from the authors. Five microliters of each
structions. One to 5 g of nuclear protein was incubatedRT reaction sample was added to 29.5 L H2O, 5 L 10	
for 30 minutes at room temperature with 100,000 cpmPCR buffer, 3 L MgCl2 (25 mmol/L), 4 L dNTPs (2.5
of the 32P labeled probe in 20 mmol/L HEPES (pH 7.9),mmol/L), 1.5 L forward primer (50 ng/mL), 1.5 L
0.3 mmol/L EDTA, 0.2 mmol/L EGTA, 80 mmol/L NaClreverse primer (50 ng/mL), and 0.5 L Taq DNA poly-
and 2 g Poly(dI-dC) (Amersham Pharmacia Biotech)merase (5 U/mL; Promega). The PCR was run for 28
in a total volume of 20 L. Competition experimentscycles without reaching the plateau phase (data not
were performed by adding unlabeled PPAR, NF-Bshown) using the following temperature profile: 95C for
and AP-1 consensus oligonucleotides in 100-fold molar10 seconds, 57C for 20 seconds, and 72C for 30 seconds.
excess to the binding reaction. The DNA-protein com-RNA samples were also analyzed for the expression of
plexes were subjected to electrophoresis on a 4% poly-the housekeeping gene GAPDH as described earlier
acrylamide gel containing 2.5% glycerol, 6.7 mmol/L[23]. Amplified cDNA fragments were separated on a
Tris-HCl (pH 7.5), 3.3 mmol/L sodium acetate and 0.11.5% agarose gel containing 1 mg/mL ethidium bromide,
mmol/L EDTA for 2.5 hours at 15C. The gel was then
and the gel was photographed under UV light using a
vacuum-dried and autoradiography was performed. Ex-
Polaroid 655 film. The amplified cDNA of the predicted posed EMSA films were quantified using a phospho-
size was isolated, subcloned, and sequenced to confirm imager Bio-Rad-GS-363 (multi-analyst software) and cor-
specificity of the reaction. To control for genomic DNA rected to the density of the probe.
artifacts, a control PCR without RT was performed. Ex-
posed films were quantified using a phosphoimager Bio-
Rad-GS-363 (multi-analyst software). Western blotting for PCNA
For Western blotting glomeruli were isolated and cen-
trifuged in 1 	 PBS. The pellet was resuspended in 100Glomerular nuclear mini-extracts and EMSA
L of Laemmli buffer [33% vol/vol 0.5 mmol/L Tris-
Kidneys were harvested after in situ perfusion with HCl pH 6.8, 66% vol/vol sodium dodecyl sulfate (SDS)
100 mL of sterile phosphate buffered saline (PBS). We 10%]. Samples were boiled for 10 minutes and centri-
adapted a method described by Sakurai et al to prepare fuged. The protein concentration was determined with
the nuclear mini-extracts and run the electrophoretic mo- a modified Lowry method (Protein DC-assay; Bio-Rad).
bility shift assay (EMSA) [24]. For extraction of nuclear To equal amounts of protein (80 g) 1⁄4 vol % Laemmli
proteins, isolated glomeruli were resuspended in 400 L buffer 2 (50% -mercaptoethanol, 50% glycerol) were
buffer A [10 mmol/L HEPES (pH 7.9), 10 mmol/L KCl, added. The solution was loaded onto a polyacrylamide
0.1 mmol/L ethylenediaminetetraacetic acid (EDTA), SDS-12% gel and electrophoresed. After completion of
0.1 mmol/L egtazic acid (EGTA), 1 mmol/L DTT, 0.5 electrophoresis, proteins were electroblotted semi-dry
mmol/L phenylmethylsulfonyl fluoride (PMSF), 10g/mL (anode buffer I, 30 mmol/L Tris, 20% methanol; anode
aprotinin, 10 g/mL leupeptin]. After homogenization buffer II, 300 mmol/L Tris, 20% methanol; cathode
with 50 strokes in a 7 mL glass-homogenizer (Wheaton) buffer, 25 mmol/L Tris, 40 mmol/L 6-amionohexane acid,
the suspension was chilled on ice for 15 minutes. Twenty- 20% methanol) for 45 minutes at 0.8 mA/cm2 to a nitro-
five microliters of 10% Noniodet P-40 were added, the cellulose membrane (Hybond ECL; Amersham). The
homogenate vigorously mixed for 10 seconds and cen- membrane was blocked in 5% nonfat dry milk in washing
trifuged at 15.000 	 g for five minutes. The pellet was buffer (1 	 PBS, 0.1% Tween 20) for one hour at room
resuspended in 100 L buffer B (20 mmol/L HEPES, temperature, then incubated for another hour with an
0.4 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, anti-rat proliferating cell nuclear assay (PCNA) antibody
1 mmol/L DTT, 1 mmol/L PMSF, 10 g/mL aprotinin, (Dakopatts M879) added to a concentration of 1:2000 in
the same buffer. After rinsing the membrane in washing10 g/mL leupeptin) and placed on ice on a shaking
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Fig. 3. Electrophoretic mobility shift assays (EMSAs) for activator protein-1 (AP-1), nuclear factor-B (NF-B) and peroxisome proliferator
activated receptor (PPAR) of nuclear extracts of isolated glomeruli. To demonstrate identical loading of radiolabeled oligos unbound probes
are shown below. The competition experiments using non-radioactive labeling are shown on the right.
buffer for 3 	 10 minutes, the secondary antibody, a nescence detection of peroxidase was performed with the
enhanced chemiluminescence (ECL) system according torabbit anti-goat–immunoglobin G conjugated to horse-
radish-peroxidase (Southern Biotechnology, Atlanta, GA, the manufacturer’s recommendations (Amersham). Films
were exposed 2 to 10 minutes at room temperature.USA) was added at a concentration of 1:1000. The lumi-
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Fig. 5. Quantification of glomerular monocyte/macrophage infiltra-
tion. Comparison of the number of infiltrating M/M into the glomerulus
in the different treatment groups. Application of troglitazone, ciglita-
zone and 15d-PGJ2 to control rats did not induce M/M recruitment in Fig. 6. Dose effects of troglitazone on glomerular monocyte/macro-
comparison to untreated controls. However, treatment of nephritic phage infiltration and MCP-1 expression. Troglitazone in doses between
rats with troglitazone and ciglitazone further increased the number of 20 and 500 mg/kg BW were used to investigate dose dependence of the
glomerular cell ED-1 positive cells in comparison to untreated nephritic effect of PPAR activation on glomerular MCP-1 mRNA expression
rats at 24 hours. In contrast, 15d-PGJ2 did not alter glomerular M/M (lower panel, RT-PCR) and glomerular monocyte recruitment 24 hours
recruitment in nephritic animals. The cell numbers are expressed as after nephritis induction (upper panel, histologic evaluation of ED-1
ED-1 positive cells/glomerular cross section. Data are given as means  cells/gsc).
SEM (#P  0.05 vs. control; *P  0.05 vs. nephritis).
nephritis activated glomerular nuclear protein binding
Statistical analysis of NF-B and AP-1, whereas glomerular PPAR DNA
Results are expressed as mean  SEM unless stated binding was reduced in nephritic rats at 24 hours (Fig. 3).
otherwise. Statistical significance was defined as P  As expected, PPAR binding was enhanced in animals
0.05. We applied Wilcoxon-Mann-Whitney test to com- treated with troglitazone, ciglitazone and 15d-PGJ2 in
pare two distinct treatment groups (that is, nephritic vs. control and nephritis groups. In nephritic animals trogli-
control or nephritic vs. treated nephritic animals). tazone and ciglitazone treatment enhanced glomerular
nuclear binding of AP-1, but did not influence glomerular
NF-B activity. In contrast, treatment of nephritic ratsRESULTS
with 15d-PGJ2 did not lead to an increase in AP-1 bind-
Induction of glomerulonephritis and treatment with ing, but reduced NF-B binding. Application of troglita-
PPAR agonists zone, ciglitazone and 15d-PGJ2 to control animals did not
Glomerular chemokine and chemokine receptor expres- influence glomerular DNA binding of the transcription
sion. Glomerular MCP-1 mRNA expression increased factors NF-B and AP-1 in comparison to the untreated
significantly in nephritic animals at 24 hours after induc- control group.
tion of the disease when compared with control animals Glomerular monocyte/macrophage infiltration. Induc-
(Fig. 1A). Treatment with troglitazone and ciglitazone tion of glomerulonephritis resulted in a significant in-
further enhanced up-regulation of MCP-1 mRNA at 24 crease in glomerular monocyte infiltration from 0.3 
hours (Figs. 1A and 2A). The mRNA expression of the 0.07 cells/glomerular cross section (c/gcs) in controls to
chemokine receptor CCR-2 (receptor for MCP-1) also 2.95  0.39 cells in nephritic rats at 24 hours (P  0.01;
was up-regulated 24 hours after induction of the disease Fig. 4 A, B and Fig. 5). Treatment of nephritic animals
(Figs. 1B and 2B). Troglitazone and ciglitazone further with troglitazone and ciglitazone further enhanced glo-
enhanced the CCR-2 expression. In contrast, 15d-PGJ2 merular monocyte recruitment at 24 hours (nephritis 
did not up-regulate MCP-1 and CCR-2 expression (Fig. 2). Tro, 4.51  0.24 c/gcs; nephritis  Cig, 4.34  0.37; P 
Application of troglitazone, ciglitazone and 15d-PGJ2 to 0.05; Figs. 4D and 5), whereas 15d-PGJ2 treatment of
control animals did not affect MCP-1 or CCR-2 mRNA nephritic animals did not alter glomerular M/M recruit-
expression. ment (Fig. 5). Application of troglitazone, ciglitazone
Activation of nuclear protein binding for PPARc, and 15d-PGJ2 to control animals did not influence glo-
NF-jB and AP-1. Electrophoretic mobility shift assay merular M/M recruitment (Figs. 4C and 5). Dose re-
sponse experiments with troglitazone demonstrated thatexperiments demonstrated that induction of glomerulo-
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Fig. 7. Effects of troglitazone on glomerular
cell proliferation. To assess the effect of the
PPAR activator troglitazone on glomerular
cell proliferation PCNA protein formation (as
a marker of cell proliferation) was analyzed
at two time points by Western blotting. Our
results reveal that troglitazone exerts only
small antiproliferative effects in the glomeru-
lus of nephritic rats. To show equal protein
loading per lane -actin expression is demon-
strated.
concentrations between 20 and 500 mg/kg BW lead to that PPAR ligands may modulate chemokine expres-
sion and inflammatory responses [10, 11] as well as trans-an increased glomerular M/M infiltration and glomerular
differentiate monocytes into macrophage foam cells [12].MCP-1 RNA expression (Fig. 6).
In studies on isolated monocytes/macrophages treatmentEffect of troglitazone on glomerular cell proliferation.
with PPAR agonists reduced tumor necrosis factor-Glomerular cell proliferation was assessed by PCNA
(TNF-), interleukin (IL)-1 and IL-6 synthesis inducedWestern blotting (Fig. 7) and immunohistologic staining
by phorbol ester [10], and inhibited the expression ofof tissue for PCNA (Figs. 8 and 9). As expected, there
several inflammatory response genes induced by inter-was an increase in PCNA protein formation in nephritic
feron- (IFN-) [11]. In a mouse model of inflammatoryanimals 24 hours and 5 days after induction of nephritis
bowel disease PPAR agonists attenuate cytokine genewhen compared to the control and troglitazone treated
expression and reduce colonic inflammation after sevenanimals (Figs. 7 to 9). Treatment of nephritic rats with
days [33].troglitazone (200 mg/kg BW/day) lead to a small de-
We were therefore interested in examining a possiblecrease of cell proliferation at both time points studied
role of different forms of PPAR activators in a model(Figs. 7 to 9). However the effect is not statistically sig-
of glomerulonephritis characterized by early monocyte/nificant (Fig. 9).
macrophage infiltration and predominant mesangial in-
volvement. In support of other observations [25, 28–29]
DISCUSSION our current study demonstrates PPARDNA binding in
Peroxisome proliferator activated receptor  ligands isolated nuclear preparations of glomeruli from control
of the thiazolidinedione group (troglitazone, pioglita- animals. In contrast to the demonstrated up-regulation in
zone, rosiglitazone) have become an important group of isolated macrophages [11], the induction of ATS-nephritis
anti-diabetic drugs in humans [6]. In experimental stud- reduces glomerular PPAR DNA binding. However,
ies in diabetic rats, PPAR activators protected against treatment of nephritic animals with the PPAR ligands
the development and progression of diabetic nephropa- troglitazone, ciglitazone and 15d-PGJ2 significantly in-
thy [7, 8]. Troglitazone decreased microalbuminuria in creases the glomerular DNA binding of PPAR, provid-
patients with diabetic nephropathy [26], but it was with- ing evidence that the PPAR ligands in the doses used
drawn from the market when reports provided evidence in our study activate glomerular PPAR.
for unexpected aggravation of hepatitis as a side effect An important chemokine for the attraction of M/M in
[27]. Although the observed renal protective effect in the anti-thymocyte antibody induced glomerulonephritis
diabetes may be an indirect effect of the antidiabetic is monocyte-chemoattractant protein-1 (MCP-1) [19–21].
and antihyperlipidemic effects of PPAR activators, it Its expression is positively correlated with the infiltration
is possible that it results from direct effects through of monocytes/macrophages in glomeruli and blockade
PPAR receptors in the kidney itself. Recent studies of MCP-1 action in vivo has been demonstrated to lead
have shown that PPAR receptors are expressed in the to a reduction of glomerular monocytes in this model
kidney [28–30] and, more specifically, in glomeruli [30]. [19, 21, 34]. In contrast to observations on isolated mono-
Several investigators have reported that PPAR expres- cytes/macrophages, where cytokine expression was re-
sion can be regulated in cultured mesangial cells [30–32]. duced by stimulation of PPAR [11], in our study of
Importantly, it has been demonstrated that PPAR is glomerular inflammation the PPAR activators troglita-
zone and ciglitazone enhanced the expression of a majorfunctionally expressed in monocytes/ macrophages and
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PPAR activators of the TZD activate the transcription
factor AP-1, which increases the expression of MCP-1,
thereby leading to an enhanced glomerular M/M recruit-
ment in this form of GN. This seems to contrast earlier
findings in isolated macrophages where treatment with
PPAR agonists reduced TNF-, IL-1 and IL-6 synthe-
sis induced by phorbol ester [10], and inhibited the ex-
pression of several inflammatory response genes induced
by IFN- [11]. However, in a recent study in vascular
smooth muscle cells PPAR agonists led to enhanced
AP-1 activity through activation of MEK/ERK pathways
by phosphatidylinositol 3-kinase [39]. Furthermore, in
mice challenged with lipopolysaccharide (LPS) PPAR
activation through TZD did not suppress cytokine pro-
duction, but rather increased blood levels of TNF- and
IL-6 [13]. In this study an important difference in the
effects observed when using thiazolidinediones and 15d-Fig. 9. Quantification of glomerular cell proliferation. Quantification
of the number of PCNA positive cells/glomerular cross section (c/gcs) PGJ2 was seen, raising doubt that the beneficial effects
5 days after induction of nephritis. Troglitazone treatment of nephritic of 15d-PGJ2 are mediated through PPAR. The resultsrats led to only a slight decrease in the number of PCNA positive cells.
of our study demonstrate different effects between theData are given as means  SEM (nephritis 6.94  0.38 vs. nephritis 
troglitazone 5.87  0.26, P  0.08). PPAR agonists of the TZD group and 15d-PGJ2 in this
model of experimental glomerulonephritis. In contrast
to the treatment with troglitazone or ciglitazone, DNA
binding of NF-B was reduced and MCP-1 expression
glomerular chemokine, MCP-1. Treatment with troglita-
was not elevated in glomeruli of nephritic rats treated
zone and ciglitazone lead to an increased number of with 15d-PGJ2. Hence, our results support findings ofinfiltrating monocytes/ macrophages. Twenty-four hours other groups where 15d-PGJ2 was shown to exert com-after induction of the disease, the enhanced glomerular plex effects beyond PPAR activation in the NF-B sig-
MCP-1 formation and monocyte recruitment was paral- naling pathway. In monocytes 15d-PGJ2 directly inhib-leled with an increased glomerular RNA expression of ited the action of IB kinase independently of PPAR
the MCP-1 receptor CCR-2, which is predominantly ex- activation [15, 16], and recently it was demonstrated in
pressed on mononuclear cells. A recent in situ hybridiza- human mesangial cells that 15d-PGJ2 also inhibits the
tion study provides evidence for the absence of CCR-2 translocation of NF-B through attenuated degradation
on resident glomerular cells [35], suggesting that the up- of IkB [40].
regulated glomerular CCR-2 RNA expression is due to Because results of previous studies show possible ef-
the infiltration of CCR-2 positive monocytes attracted fects of PPAR agonists on cell proliferation [41, 42],
by MCP-1. we measured proliferation cell nuclear antigen (PCNA)
To determine which transcription factors might be reg- as a marker of cell proliferation in our model of GN at 24
ulated by PPAR activation in this form of glomerulone- hours and five days after induction of disease. However,
phritis and, more specifically, drive the expression of the glomerular PCNA determined by Western blotting and
chemokine MCP-1, we investigated the glomerular DNA immunohistology was not altered significantly in ne-
binding of the transcription factors NF-B and AP-1. phritic animals when they were treated with troglitazone.
NF-B and AP-1 are important regulators of MCP-1 In summary, our results demonstrate that treatment
gene expression [36, 37], and recent studies have shown with the PPAR agonists of the TZD group (troglitazone
that PPAR can directly influence the activity of NF-B and ciglitazone) but not 15d-PGJ2 enhances MCP-1 for-
and AP-1 in macrophages [11]. In addition, it seems mation and M/M recruitment in the induction phase of a
unlikely that PPAR activation may directly regulate rat model of mesangial proliferative glomerulonephritis.
the transcription of the C-C chemokine MCP-1 because Our data suggest that these effects may be partly medi-
no PPRE element is reported in the 5region of the ated through an increased binding activity of the nuclear
MCP-1 gene. Our results further confirm an earlier study transcription factor AP-1. It seems possible that PPAR
in the ATS model of glomerulonephritis demonstrating agonists of the TZD group may lead to an enhanced
an increased glomerular activation of NF-B and AP-1 attraction of inflammatory cells in glomerulonephritis.
[38]. We show that the activity of NF-B was unaffected The findings of this study underscore the need for a
by troglitazone and ciglitazone, whereas the activity of careful evaluation of possible deleterious effects of
PPAR activators in human glomerulonephritis.AP-1 was markedly increased. Our results suggest that
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